Detection of immunogenic cell death and its relevance for cancer therapy.

Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, Zhao L, Spisek R, Kroemer G, Galluzzi L. · 2020

Read Detection of immunogenic cell death and its relevance for cancer therapy. by Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, Zhao L, Spisek R, Kroemer G, Galluzzi L. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7691519.txt.

Introduction

Fucikova and co-authors explain how to detect a form of cancer cell death that alerts the immune system. In this death, called immunogenic cell death, dying tumor cells emit warning signals. These signals draw in immune cells that present tumor parts and start an attack. Some chemo and radiation drugs can trigger it.

The authors list the key signals, such as surface calreticulin and released ATP. They also name cell stress signs that back up the call. Methods for use in lab dishes and in tissue samples are set out step by step. The aim is to find new drugs and craft personal treatment mixes for patients.

Catalog record

CREATORFucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, Zhao L, Spisek R, Kroemer G, Galluzzi L.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE75 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7691519

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Detection of immunogenic cell death and its relevance for cancer therapy By Jitka Fucikova, Oliver Kepp, Lenka Kasikova, Giulia Petroni, Takahiro Yamazaki, Peng Liu, Liwei Zhao, Radek Spisek, Guido Kroemer, Lorenzo Galluzzi Published in: Cell Death & Disease DOI: 10.1038/s41419-020-03221-2 ABSTRACT Abstract Chemotherapy, radiation therapy, as well as targeted anticancer agents can induce clinically relevant tumor-targeting immune responses, which critically rely on the antigenicity of malignant cells and their capacity to generate adjuvant signals. In particular, immunogenic cell death (ICD) is accompanied by the exposure and release of numerous damage-associated molecular patterns (DAMPs), which altogether confer a robust adjuvanticity to dying cancer cells, as they favor the recruitment and activation of antigen-presenting cells. ICD-associated DAMPs include surface-exposed calreticulin (CALR) as well as secreted ATP, annexin A1 (ANXA1), type I interferon, and high-mobility group box 1 (HMGB1). Additional hallmarks of ICD encompass the phosphorylation of eukaryotic translation initiation factor 2 subunit-α (EIF2S1, better known as eIF2α), the activation of autophagy, and a global arrest in transcription and translation. Here, we outline methodological approaches for measuring ICD markers in vitro and ex vivo for the discovery of next-generation antineoplastic agents, the development of personalized anticancer regimens, and the identification of optimal therapeutic combinations for the clinical management of cancer. Subject terms: Cancer immunotherapy, Drug discovery, Immune cell death FACTS - Immunogenic cell death (ICD) can initiate adaptive immune responses, because it is accompanied by the emission of adjuvant-like signals commonly known as damage-associated molecular patterns (DAMPs). - Key DAMPs for cell death to be perceived as immunogenic include calreticulin, HMGB1, ATP, ANXA1, and type I IFN. - DAMP emission by cells undergoing ICD often relies on the activation of intracellular responses of adaptation to stress. - Although detecting DAMP emission from dying cells informs on the potential immunogenicity of cell death, in vivo assays are required to validate bona fide instances of ICD. OPEN QUESTIONS - Does a core set of DAMPs common to all instances of ICD exist? - Can we harness transcriptional signatures of pattern recognition receptor (PRR) signaling to assess DAMP emission in patient biopsies? - Will therapeutic strategies specifically conceived to restore the immunogenicity of cell death enter the clinical practice for cancer therapy? INTRODUCTION The emergence and progression of human neoplasms strongly depends on the interaction between cancer cells and their microenvironment, especially in its immunological components1–7. Immunosurveillance is generally mediated by type 1 CD4+ T-helper (TH1) cells and CD8+ cytotoxic T lymphocytes (CTLs), which specifically recognize antigenic epitopes emerging during malignant transformation and tumor progression8–13. Specifically, neoplastic cells can become visible to the adaptive immune system as a consequence of non-synonymous mutations in the coding region of actively expressed genes (leading to antigens that are not covered by central tolerance) or the ectopic expression of otherwise normal antigens for which central tolerance is leaky9,14–17. Thus, the (neo)antigenic profile of a tumor is a key determinant of anticancer immune responses18–20, as demonstrated by the fact that several solid tumors become resistant to immunotherapy with immune checkpoint inhibitors (ICIs) by acquiring defects in the antigen presentation machinery21–25. However, antigenicity is not sufficient for malignant cells to initiate anticancer immunity, as antigen presentation by dendritic cells (DCs) in the absence of co-stimulatory signals to T cells generally results in the establishment of immunological tolerance26–30. Thus, malignant cells can also escape immunosurveillance by losing their capacity to promote the recruitment and functional maturation of DCs or their precursors, a feature that is cumulatively referred to as adjuvanticity31–33. Although the adjuvanticity of infected cells mostly originates from microbial products commonly referred to as microbe-associated molecular patterns (MAMPs; e.g., lipopolysaccharide)34–36, malignant cells mediate chemotactic and immunostimulatory effects by emitting the so-called damage-associated molecular patterns (DAMPs) and secreting cytokines as they adapt or succumb to microenvironmental perturbations16,37,38. Immunogenic cell death (ICD) represents a functionally unique response pattern that comprises the induction of organellar and cellular stress, and culminates with cell death accompanied by the exposure, active secretion, or passive release of numerous DAMPs16,37,39–41. The spatiotemporally defined emission of DAMPs in the course of ICD and their binding to specific pattern recognition receptors (PRRs) expressed by DCs initiates a cellular cascade that ultimately results in the activation of both innate and adaptive immune responses34,42–44. In line with this notion, accumulating preclinical and clinical evidence indicates that various DAMPs and DAMP-associated processes may have prognostic and predictive value for patients affected by a variety of tumors45. Moreover, there is ample evidence that treatment-driven ICD can elicit anticancer immune responses that reinforce the therapeutic effects of conventional anticancer chemotherapies and radiotherapy46–49. So far, however, only a few bona fide ICD inducers have been successfully employed in the clinic as therapeutics (Table 1)46,50. These agents may be particularly relevant to initiate anticancer immune responses that can be actioned by ICIs or other forms of immunotherapy in the context of combinatorial treatment regimens46,51–55, as demonstrated in some clinical56,57 and numerous preclinical58–60 studies. In line with this notion, numerous Food and Drug Administration-approved ICD inducers are currently being investigated in off-label oncological settings, especially in combination with ICIs or other immunotherapeutics61–65. [Table: Immunogenic cell death inducers commonly employed as conventional chemotherapeuticsa.] Thus, the development of methodological approaches and platforms for identifying novel ICD inducers should accelerate the development of next-generation anticancer therapeutics, ultimately improving the clinical management of a large population of oncological patients. MAIN HALLMARKS OF ICD ICD can be induced by different stressors, including but not limited to (1) intracellular pathogens66–68; (2) conventional chemotherapeutics such as anthracyclines, DNA-damaging agents, and proteasomal inhibitors50,69–72; (3) targeted anticancer agents such as the tyrosine kinase inhibitor crizotinib, the epidermal growth factor receptor-specific monoclonal antibody cetuximab and poly-ADP-ribose polymerase (PARP) inhibitors59,73–76; and (4) numerous physical modalities, encompassing hypericin- and redaporfin-based photodynamic therapy, extracorporeal photochemotherapy, various forms of ionizing radiation, high hydrostatic pressure, and severe heat shock77–81. DAMPs emitted in the course of ICD include endoplasmic reticulum (ER) chaperones such as calreticulin (CALR) and heat-shock proteins (HSPs), which are exposed on the cell surface, the non-histone chromatin-binding protein high-mobility group box 1 (HMGB1), the cytoplasmic protein annexin A1 (ANXA1), and the small metabolite ATP that are liberated from dying cells into the extracellular space, as well as type I interferons (IFNs) that are released upon de novo synthesis38,82–84. DAMPs can be recognized by both the innate and adaptive immune systems via distinct PRRs driving chemoattraction, homing, activation, and/or maturation, ultimately resulting in the cross-presentation of tumor antigens to CD8+ CTLs in the context of robust immunostimulation34,43. Other hallmarks of ICD include the phosphorylation of eukaryotic translation initiation factor 2 subunit-α (EIF2S1, better known as eIF2α), the activation of autophagy, and a global arrest in transcription and translation85–88. Importantly, not all ICD inducers activate the same stress responses and hence elicit the same molecular signals16. Thus, for instance, although autophagy is strictly required for anthracycline-driven cancer cell death to be perceived as immunogenic86, the same does not hold true for the demise of cancer cells exposed to ionizing radiation89 (Fig. 1). [Figure: Main hallmarks of ICD.Different inducers of immunogenic cell death (ICD) have been shown to elicit incompletely overlapping molecular signatures with respect to ICD biomarkers. This not only reinforces the need for the simultaneous assessment of multiple surrogate ICD biomarkers in the context

Read the complete text